T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-09-14

AUTHORS

Lisa M. Pörtner, Kathrin Schönberg, Maryam Hejazi, Daniela Brünnert, Frank Neumann, Lars Galonska, Uwe Reusch, Melvyn Little, Rainer Haas, Markus Uhrberg

ABSTRACT

Bispecific tetravalent antibodies (TandAb) directed against the B cell surface marker CD19 and activating receptors on T or NK cells (CD19 × CD3 or CD19 × CD16) have shown promising effects in vitro and in preclinical studies. Here, we examine the cytotoxic efficacy of T and NK cells from patients with B cell Non-Hodgkin′s Lymphoma (NHL) against B-lymphoma cells following the binding of the matching TandAb. The addition of CD19 × CD16 TandAb led to a threefold increase in NK cell activation in the presence of B-lymphoma cells. Similarly, T cells displayed a sevenfold increase in cytotoxic activity after the addition of CD19 × CD3 TandAb. Comparison of T and NK cell effector function of patients and healthy controls showed comparable levels of cytotoxic activity in response to lymphoma cells and no reduction in functional activity due to age, disease stage or the type and amount of previous therapy. Thus, T and NK cells of patients with B cell NHL are fully capable of being activated by therapeutic crosslinking antibodies. These results provide a rationale for the use of TandAbs for patients with B cell NHL, particularly in cases where remission with minimal residual disease could be achieved by cytotoxic chemotherapy. More... »

PAGES

1869-1875

References to SciGraph publications

Journal

TITLE

Cancer Immunology, Immunotherapy

ISSUE

10

VOLUME

61

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00262-012-1339-9

DOI

http://dx.doi.org/10.1007/s00262-012-1339-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010393117

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22976535


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Bispecific", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD19", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CD3 Complex", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cells, Cultured", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "GPI-Linked Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Killer Cells, Natural", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Activation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, B-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, IgG", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Lymphocytes, Cytotoxic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "P\u00f6rtner", 
        "givenName": "Lisa M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute for Transplantation Diagnostics and Cellular Therapeutics, Heinrich-Heine-University, Moorenstr. 5, 40255, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Institute for Transplantation Diagnostics and Cellular Therapeutics, Heinrich-Heine-University, Moorenstr. 5, 40255, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sch\u00f6nberg", 
        "givenName": "Kathrin", 
        "id": "sg:person.0624553065.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624553065.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute for Transplantation Diagnostics and Cellular Therapeutics, Heinrich-Heine-University, Moorenstr. 5, 40255, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Institute for Transplantation Diagnostics and Cellular Therapeutics, Heinrich-Heine-University, Moorenstr. 5, 40255, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hejazi", 
        "givenName": "Maryam", 
        "id": "sg:person.0763726723.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763726723.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Br\u00fcnnert", 
        "givenName": "Daniela", 
        "id": "sg:person.01107771133.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107771133.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neumann", 
        "givenName": "Frank", 
        "id": "sg:person.01052437231.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052437231.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Galonska", 
        "givenName": "Lars", 
        "id": "sg:person.01102402601.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102402601.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Affimed Therapeutics AG, Heidelberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.432627.6", 
          "name": [
            "Affimed Therapeutics AG, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reusch", 
        "givenName": "Uwe", 
        "id": "sg:person.0701042661.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701042661.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Affimed Therapeutics AG, Heidelberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.432627.6", 
          "name": [
            "Affimed Therapeutics AG, Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Little", 
        "givenName": "Melvyn", 
        "id": "sg:person.0704410246.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704410246.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haas", 
        "givenName": "Rainer", 
        "id": "sg:person.01127414674.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute for Transplantation Diagnostics and Cellular Therapeutics, Heinrich-Heine-University, Moorenstr. 5, 40255, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Institute for Transplantation Diagnostics and Cellular Therapeutics, Heinrich-Heine-University, Moorenstr. 5, 40255, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uhrberg", 
        "givenName": "Markus", 
        "id": "sg:person.01074343516.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074343516.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00262-005-0001-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029966967", 
          "https://doi.org/10.1007/s00262-005-0001-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-60327-302-2_14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035975320", 
          "https://doi.org/10.1007/978-1-60327-302-2_14"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-09-14", 
    "datePublishedReg": "2012-09-14", 
    "description": "Bispecific tetravalent antibodies (TandAb) directed against the B cell surface marker CD19 and activating receptors on T or NK cells (CD19\u00a0\u00d7\u00a0CD3 or CD19\u00a0\u00d7\u00a0CD16) have shown promising effects in vitro and in preclinical studies. Here, we examine the cytotoxic efficacy of T and NK cells from patients with B cell Non-Hodgkin\u2032s Lymphoma (NHL) against B-lymphoma cells following the binding of the matching TandAb. The addition of CD19\u00a0\u00d7\u00a0CD16 TandAb led to a threefold increase in NK cell activation in the presence of B-lymphoma cells. Similarly, T cells displayed a sevenfold increase in cytotoxic activity after the addition of CD19\u00a0\u00d7\u00a0CD3 TandAb. Comparison of T and NK cell effector function of patients and healthy controls showed comparable levels of cytotoxic activity in response to lymphoma cells and no reduction in functional activity due to age, disease stage or the type and amount of previous therapy. Thus, T and NK cells of patients with B cell NHL are fully capable of being activated by therapeutic crosslinking antibodies. These results provide a rationale for the use of TandAbs for patients with B cell NHL, particularly in cases where remission with minimal residual disease could be achieved by cytotoxic chemotherapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00262-012-1339-9", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096240", 
        "issn": [
          "0340-7004", 
          "1432-0851"
        ], 
        "name": "Cancer Immunology, Immunotherapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "61"
      }
    ], 
    "keywords": [
      "B-cell non-Hodgkin lymphoma", 
      "cell non-Hodgkin lymphoma", 
      "non-Hodgkin lymphoma", 
      "NK cells", 
      "B lymphoma cells", 
      "NK cell effector functions", 
      "B-cell NHL patients", 
      "surface markers CD19", 
      "NK cell activation", 
      "cell effector functions", 
      "minimal residual disease", 
      "cytotoxic activity", 
      "previous therapy", 
      "cytotoxic chemotherapy", 
      "NHL patients", 
      "residual disease", 
      "disease stage", 
      "healthy controls", 
      "T cells", 
      "preclinical studies", 
      "effector functions", 
      "patients", 
      "cell activation", 
      "tetravalent antibody", 
      "CD19", 
      "lymphoma cells", 
      "promising effects", 
      "functional activity", 
      "cytotoxic efficacy", 
      "CD16", 
      "CD3", 
      "threefold increase", 
      "antibodies", 
      "comparable levels", 
      "cells", 
      "sevenfold increase", 
      "Tandab", 
      "remission", 
      "chemotherapy", 
      "lymphoma", 
      "therapy", 
      "disease", 
      "activity", 
      "receptors", 
      "efficacy", 
      "age", 
      "vitro", 
      "cytotoxicity", 
      "activation", 
      "increase", 
      "response", 
      "rationale", 
      "levels", 
      "addition", 
      "control", 
      "cases", 
      "study", 
      "binding", 
      "reduction", 
      "effect", 
      "presence", 
      "use", 
      "stage", 
      "function", 
      "types", 
      "comparison", 
      "results", 
      "amount", 
      "matching"
    ], 
    "name": "T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 \u00d7 CD3 or CD19 \u00d7 CD16", 
    "pagination": "1869-1875", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010393117"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00262-012-1339-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22976535"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00262-012-1339-9", 
      "https://app.dimensions.ai/details/publication/pub.1010393117"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_569.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00262-012-1339-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00262-012-1339-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00262-012-1339-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00262-012-1339-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00262-012-1339-9'


 

This table displays all metadata directly associated to this object as RDF triples.

277 TRIPLES      21 PREDICATES      114 URIs      104 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00262-012-1339-9 schema:about N028e8a6fc56543fdae8bf775bdabca8e
2 N0ef985ffb32847ad9f6504861203bc58
3 N2a77919215f94a8f954f551cca1c41f0
4 N41629c7ca4024fe1890e2cb570ebff70
5 N5c02cabdf8b84fa996de6ef73737b07e
6 N6ef352136aec49589f4337b57b1aa788
7 N72e2e436686b45e7b8b2fae28efd565f
8 N7cc8ee1b18b84c46b974e25d01a87d35
9 N7d72eefe4c3248fc91c2ab9b27c55e5c
10 N7e9bd1dfa5e94e3ba1821b872b56e06c
11 N912095a78ffb458fb498fd1f9d6821d2
12 N9cc652054ae84eb4be0238c459738e3f
13 Na1cebd74d6704b069eca60ae43f67f56
14 Nae987ff6bea1426a8495069fb0d80940
15 Nb42964c9689f49e3afd3981e34c86907
16 Nc76a53fdeac44addafd14f4b37d8fc34
17 Ncaadac61c7664078a2645dadd50b7571
18 Nfe832eb2ed3e4133bcb6bcac90be918e
19 anzsrc-for:11
20 anzsrc-for:1107
21 schema:author N0d0348b7a44d4c8a9031b5f7fe500515
22 schema:citation sg:pub.10.1007/978-1-60327-302-2_14
23 sg:pub.10.1007/s00262-005-0001-1
24 schema:datePublished 2012-09-14
25 schema:datePublishedReg 2012-09-14
26 schema:description Bispecific tetravalent antibodies (TandAb) directed against the B cell surface marker CD19 and activating receptors on T or NK cells (CD19 × CD3 or CD19 × CD16) have shown promising effects in vitro and in preclinical studies. Here, we examine the cytotoxic efficacy of T and NK cells from patients with B cell Non-Hodgkin′s Lymphoma (NHL) against B-lymphoma cells following the binding of the matching TandAb. The addition of CD19 × CD16 TandAb led to a threefold increase in NK cell activation in the presence of B-lymphoma cells. Similarly, T cells displayed a sevenfold increase in cytotoxic activity after the addition of CD19 × CD3 TandAb. Comparison of T and NK cell effector function of patients and healthy controls showed comparable levels of cytotoxic activity in response to lymphoma cells and no reduction in functional activity due to age, disease stage or the type and amount of previous therapy. Thus, T and NK cells of patients with B cell NHL are fully capable of being activated by therapeutic crosslinking antibodies. These results provide a rationale for the use of TandAbs for patients with B cell NHL, particularly in cases where remission with minimal residual disease could be achieved by cytotoxic chemotherapy.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf N900ede927cec43eaa3f6942e7ca2a045
30 Nd0b09534b8aa41e9a78c49f12e3757bc
31 sg:journal.1096240
32 schema:keywords B lymphoma cells
33 B-cell NHL patients
34 B-cell non-Hodgkin lymphoma
35 CD16
36 CD19
37 CD3
38 NHL patients
39 NK cell activation
40 NK cell effector functions
41 NK cells
42 T cells
43 Tandab
44 activation
45 activity
46 addition
47 age
48 amount
49 antibodies
50 binding
51 cases
52 cell activation
53 cell effector functions
54 cell non-Hodgkin lymphoma
55 cells
56 chemotherapy
57 comparable levels
58 comparison
59 control
60 cytotoxic activity
61 cytotoxic chemotherapy
62 cytotoxic efficacy
63 cytotoxicity
64 disease
65 disease stage
66 effect
67 effector functions
68 efficacy
69 function
70 functional activity
71 healthy controls
72 increase
73 levels
74 lymphoma
75 lymphoma cells
76 matching
77 minimal residual disease
78 non-Hodgkin lymphoma
79 patients
80 preclinical studies
81 presence
82 previous therapy
83 promising effects
84 rationale
85 receptors
86 reduction
87 remission
88 residual disease
89 response
90 results
91 sevenfold increase
92 stage
93 study
94 surface markers CD19
95 tetravalent antibody
96 therapy
97 threefold increase
98 types
99 use
100 vitro
101 schema:name T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16
102 schema:pagination 1869-1875
103 schema:productId N0efb7601e46b4ddc8e9b869582a8dee7
104 N1bb95d79e7484f40a270ec8ad2d2e47f
105 N72f95b602abd409eb285b269647c7ab8
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010393117
107 https://doi.org/10.1007/s00262-012-1339-9
108 schema:sdDatePublished 2022-08-04T16:59
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N70e7e9c98ae94ea9953a93050e155930
111 schema:url https://doi.org/10.1007/s00262-012-1339-9
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N028e8a6fc56543fdae8bf775bdabca8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Cells, Cultured
117 rdf:type schema:DefinedTerm
118 N0c9a78c0c1bf4a0bbb023403973bd0b6 rdf:first sg:person.01074343516.09
119 rdf:rest rdf:nil
120 N0d0348b7a44d4c8a9031b5f7fe500515 rdf:first N2c42936b95dd4d6da871beda6830cc13
121 rdf:rest N71547ce188d84bf49076c7b9ad316d25
122 N0ef985ffb32847ad9f6504861203bc58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Lymphocyte Activation
124 rdf:type schema:DefinedTerm
125 N0efb7601e46b4ddc8e9b869582a8dee7 schema:name pubmed_id
126 schema:value 22976535
127 rdf:type schema:PropertyValue
128 N1bb95d79e7484f40a270ec8ad2d2e47f schema:name dimensions_id
129 schema:value pub.1010393117
130 rdf:type schema:PropertyValue
131 N29901b54b4734cd89acd2b7725c0c7d5 rdf:first sg:person.0763726723.57
132 rdf:rest N6191ec4fce2f4a0b8b8404fcd95ed661
133 N2a77919215f94a8f954f551cca1c41f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Antineoplastic Agents
135 rdf:type schema:DefinedTerm
136 N2c42936b95dd4d6da871beda6830cc13 schema:affiliation grid-institutes:grid.411327.2
137 schema:familyName Pörtner
138 schema:givenName Lisa M.
139 rdf:type schema:Person
140 N41629c7ca4024fe1890e2cb570ebff70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Male
142 rdf:type schema:DefinedTerm
143 N5c02cabdf8b84fa996de6ef73737b07e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Female
145 rdf:type schema:DefinedTerm
146 N6191ec4fce2f4a0b8b8404fcd95ed661 rdf:first sg:person.01107771133.55
147 rdf:rest Ned906d1f40ce46e0a8f1c815b1aefb27
148 N6ef352136aec49589f4337b57b1aa788 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Receptors, IgG
150 rdf:type schema:DefinedTerm
151 N70e7e9c98ae94ea9953a93050e155930 schema:name Springer Nature - SN SciGraph project
152 rdf:type schema:Organization
153 N71547ce188d84bf49076c7b9ad316d25 rdf:first sg:person.0624553065.26
154 rdf:rest N29901b54b4734cd89acd2b7725c0c7d5
155 N72e2e436686b45e7b8b2fae28efd565f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Antigens, CD19
157 rdf:type schema:DefinedTerm
158 N72f95b602abd409eb285b269647c7ab8 schema:name doi
159 schema:value 10.1007/s00262-012-1339-9
160 rdf:type schema:PropertyValue
161 N7cc8ee1b18b84c46b974e25d01a87d35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Middle Aged
163 rdf:type schema:DefinedTerm
164 N7d72eefe4c3248fc91c2ab9b27c55e5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name GPI-Linked Proteins
166 rdf:type schema:DefinedTerm
167 N7e9bd1dfa5e94e3ba1821b872b56e06c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Aged
169 rdf:type schema:DefinedTerm
170 N900ede927cec43eaa3f6942e7ca2a045 schema:volumeNumber 61
171 rdf:type schema:PublicationVolume
172 N912095a78ffb458fb498fd1f9d6821d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name T-Lymphocytes, Cytotoxic
174 rdf:type schema:DefinedTerm
175 N9cc652054ae84eb4be0238c459738e3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name CD3 Complex
177 rdf:type schema:DefinedTerm
178 Na1cebd74d6704b069eca60ae43f67f56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Lymphoma, B-Cell
180 rdf:type schema:DefinedTerm
181 Na3dd513298e74fe09ffb09297f296a26 rdf:first sg:person.0704410246.85
182 rdf:rest Ne5d551dc04c04adda55fec7e200860a3
183 Nae987ff6bea1426a8495069fb0d80940 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Adult
185 rdf:type schema:DefinedTerm
186 Nb42964c9689f49e3afd3981e34c86907 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Humans
188 rdf:type schema:DefinedTerm
189 Nbd6594d024244700aa0f94079bae4701 rdf:first sg:person.0701042661.32
190 rdf:rest Na3dd513298e74fe09ffb09297f296a26
191 Nc76a53fdeac44addafd14f4b37d8fc34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Antibodies, Bispecific
193 rdf:type schema:DefinedTerm
194 Ncaadac61c7664078a2645dadd50b7571 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Aged, 80 and over
196 rdf:type schema:DefinedTerm
197 Nd0b09534b8aa41e9a78c49f12e3757bc schema:issueNumber 10
198 rdf:type schema:PublicationIssue
199 Ne5d551dc04c04adda55fec7e200860a3 rdf:first sg:person.01127414674.14
200 rdf:rest N0c9a78c0c1bf4a0bbb023403973bd0b6
201 Ned2a4ec72ab2449dac0fcde05049e865 rdf:first sg:person.01102402601.56
202 rdf:rest Nbd6594d024244700aa0f94079bae4701
203 Ned906d1f40ce46e0a8f1c815b1aefb27 rdf:first sg:person.01052437231.22
204 rdf:rest Ned2a4ec72ab2449dac0fcde05049e865
205 Nfe832eb2ed3e4133bcb6bcac90be918e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Killer Cells, Natural
207 rdf:type schema:DefinedTerm
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
212 schema:name Immunology
213 rdf:type schema:DefinedTerm
214 sg:journal.1096240 schema:issn 0340-7004
215 1432-0851
216 schema:name Cancer Immunology, Immunotherapy
217 schema:publisher Springer Nature
218 rdf:type schema:Periodical
219 sg:person.01052437231.22 schema:affiliation grid-institutes:grid.411327.2
220 schema:familyName Neumann
221 schema:givenName Frank
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052437231.22
223 rdf:type schema:Person
224 sg:person.01074343516.09 schema:affiliation grid-institutes:grid.411327.2
225 schema:familyName Uhrberg
226 schema:givenName Markus
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074343516.09
228 rdf:type schema:Person
229 sg:person.01102402601.56 schema:affiliation grid-institutes:grid.411327.2
230 schema:familyName Galonska
231 schema:givenName Lars
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102402601.56
233 rdf:type schema:Person
234 sg:person.01107771133.55 schema:affiliation grid-institutes:grid.411327.2
235 schema:familyName Brünnert
236 schema:givenName Daniela
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107771133.55
238 rdf:type schema:Person
239 sg:person.01127414674.14 schema:affiliation grid-institutes:grid.411327.2
240 schema:familyName Haas
241 schema:givenName Rainer
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14
243 rdf:type schema:Person
244 sg:person.0624553065.26 schema:affiliation grid-institutes:grid.411327.2
245 schema:familyName Schönberg
246 schema:givenName Kathrin
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624553065.26
248 rdf:type schema:Person
249 sg:person.0701042661.32 schema:affiliation grid-institutes:grid.432627.6
250 schema:familyName Reusch
251 schema:givenName Uwe
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701042661.32
253 rdf:type schema:Person
254 sg:person.0704410246.85 schema:affiliation grid-institutes:grid.432627.6
255 schema:familyName Little
256 schema:givenName Melvyn
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704410246.85
258 rdf:type schema:Person
259 sg:person.0763726723.57 schema:affiliation grid-institutes:grid.411327.2
260 schema:familyName Hejazi
261 schema:givenName Maryam
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763726723.57
263 rdf:type schema:Person
264 sg:pub.10.1007/978-1-60327-302-2_14 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035975320
265 https://doi.org/10.1007/978-1-60327-302-2_14
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/s00262-005-0001-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029966967
268 https://doi.org/10.1007/s00262-005-0001-1
269 rdf:type schema:CreativeWork
270 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
271 Institute for Transplantation Diagnostics and Cellular Therapeutics, Heinrich-Heine-University, Moorenstr. 5, 40255, Düsseldorf, Germany
272 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
273 Institute for Transplantation Diagnostics and Cellular Therapeutics, Heinrich-Heine-University, Moorenstr. 5, 40255, Düsseldorf, Germany
274 rdf:type schema:Organization
275 grid-institutes:grid.432627.6 schema:alternateName Affimed Therapeutics AG, Heidelberg, Germany
276 schema:name Affimed Therapeutics AG, Heidelberg, Germany
277 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...